Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021
Four To Go Public Via SPAC, Including Pardes Biosciences
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
